Predictors of overall survival in advanced biliary tract cancer in the phase 3 TOPAZ-1 study

杜瓦卢马布 医学 肿瘤科 内科学 中期分析 吉西他滨 胆道癌 总体生存率 安慰剂 癌症 析因分析 生存分析 比例危险模型 免疫疗法 临时的 临床研究阶段 顺铂 易普利姆玛 护理标准 临床试验 子群分析 前列腺癌 免疫系统 免疫检查点 放化疗 癌 多元分析 性能状态 放射治疗 预后变量
作者
Aiwu Ruth He,Mohamed Bouattour,Vineet Govinda Gupta,Ludovic Evesque,David Bing Zhen,Joon Oh Park,Aumkhae Sookprasert,Alejandro Salvatierra,Gina M. Vaccaro,Sang Cheul Oh,Sandra Anabel Ostoich,Taroh Satoh,Aleksandra Kuzko,Magdalena Żotkiewicz,Nana Rokutanda,Do‐Youn Oh
出处
期刊:Hepatology communications [Lippincott Williams & Wilkins]
卷期号:10 (1) 被引量:1
标识
DOI:10.1097/hc9.0000000000000868
摘要

INTRODUCTION TOPAZ-1 (NCT03875235) was the first large, phase 3 study to show that combining durvalumab, an immune checkpoint inhibitor, with gemcitabine and cisplatin (GemCis) could improve overall survival (OS) versus GemCis alone, the prior standard of care (SoC), in advanced biliary tract cancers (aBTCs).1 At the pre-planned interim analysis of TOPAZ-1 [primary analysis, data cut-off (DCO) August 11, 20211], durvalumab plus GemCis showed a significant improvement in OS versus placebo plus GemCis, with no additional toxicity observed. An updated analysis (6-month follow-up; DCO February 25, 2022) further confirmed the favorable benefit-risk profile.2 Based on the findings from TOPAZ-1, durvalumab plus GemCis has become a SoC for aBTCs. However, the factors prognostic for OS in aBTCs, or those predictive of survival following immune checkpoint inhibitor treatment, remain poorly defined.3,4 Although several patient-related and disease-related factors have been identified as potentially prognostic for survival benefit in aBTCs, none have been definitively confirmed.5 This post-hoc analysis aimed to assess patient-related and disease-related factors, and evaluate their potential prognostic or predictive value, in participants with aBTCs treated with durvalumab plus GemCis versus placebo plus GemCis in TOPAZ-1. METHODS The design and eligibility criteria of TOPAZ-1 have been described previously1 and are summarized in the Supplemental Digital Content, https://links.lww.com/HC9/C208. The DCO for this analysis was February 25, 2022. A list of potential prognostic factors for OS was compiled through a literature search of articles published between January 01, 2022, and March 14, 2024, and included pre-specified factors from the original TOPAZ-1 study. These factors were evaluated for their potential to predict OS benefit following treatment with durvalumab plus GemCis versus placebo plus GemCis, in participants of the TOPAZ-1 study.1 Analyses were based on the full analysis set (FAS), with additional prognostic sensitivity analyses conducted using both the FAS and the complete case set (CCS; excluding participants with ≥1 missing clinical or laboratory measurement). Detailed methods are provided in the Supplemental Digital Content, https://links.lww.com/HC9/C208. RESULTS A total of 685 participants were randomized to durvalumab plus GemCis (n = 341) or placebo plus GemCis (n = 344) and comprised the FAS; the CCS comprised 205 and 211 participants, respectively. Baseline demographics, disease characteristics, clinical factors, and laboratory factors were generally balanced across treatment groups and data sets (Supplemental Table S1, https://links.lww.com/HC9/C208). The OS HR for durvalumab plus GemCis versus placebo plus GemCis, adjusted for stratification factors only, was 0.76 (95% CI: 0.64–0.91)2 in the FAS and 0.74 (95% CI: 0.59–0.93) in the CCS. The following factors were identified as potentially prognostic for OS in the FAS: neutrophil-to-lymphocyte ratio (NLR), cancer antigen 19-9 (CA 19-9), disease status (initially unresectable vs. recurrent), primary tumor location, lactate dehydrogenase, albumin, carcinoembryonic antigen (CEA), and total bilirubin (Supplemental Table S2, https://links.lww.com/HC9/C208). After adjusting for these factors, the OS HR was 0.70 (95% CI: 0.56–0.88). The results of the sensitivity analyses based on the FAS and CCS are reported in Supplemental Table S2, https://links.lww.com/HC9/C208. In the predictive analysis, OS HRs for durvalumab plus GemCis versus placebo plus GemCis were <1 across all factors assessed, and all interaction p values exceeded 0.05 (Figure 1). Results for the predictive analysis of the TOPAZ-1 stratification factors and pre-specified demographic and disease characteristics have been previously reported.1FIGURE 1: Factors predictive of overall survival benefit with durvalumab plus gemcitabine and cisplatin in TOPAZ-1 in the full analysis set. †High expression = tumor area positivity <1%; low expression = tumor area positivity ≥1%. ‡Cut-offs were selected based on You MS, et al. 2019.6 §The cut-off used to split participants into subgroups was the median value within participants in the TOPAZ-1 study. HRs were estimated by an unstratified Cox proportional hazards model with treatment as the sole covariate. CIs were calculated using a profile likelihood approach. The p-value was derived from an interaction term in an unstratified Cox proportional hazards model with treatment, factor, and their interaction (treatment by factor) as covariates. Abbreviations: CA 19-9, cancer antigen 19-9; CEA, carcinoembryonic antigen; eCCA, extrahepatic cholangiocarcinoma; ECOG PS, Eastern Cooperative Oncology Group performance status; GBC, gallbladder cancer; iCCA, intrahepatic cholangiocarcinoma; LDH, lactate dehydrogenase; NLR, neutrophil (109/L) to lymphocyte (109/L) ratio; OS, overall survival; PD-L1, programmed cell death ligand-1.DISCUSSION Baseline factors and OS HRs for durvalumab plus GemCis versus placebo plus GemCis were consistent in the FAS and CCS. The potential prognostic factors identified in this analysis were generally consistent with prior findings.6–8 None of the factors tested were found to be predictive for differential OS benefit following treatment with durvalumab plus GemCis. Previous literature has reported NLR ≥3, CEA ≥5 ng/mL, and CA 19-9 ≥500 U/mL as prognostic factors for OS in patients with gallbladder cancer treated with GemCis.6 This aligns with our findings using the Akaike information criterion (AIC) and the FAS. However, in AIC-based sensitivity analyses using the CCS, CEA was not prognostic. Missing data may have influenced these results, as ~10% of values were missing for CEA (9.5%), CA 19-9 (8.8%), and programmed cell death ligand-1 (10.7%), compared with <1.9% for other variables. As the CCS was a subset of the FAS, more data were available in the FAS, allowing for a more robust analysis. The adjusted OS HRs remained consistent across models in this analysis and with prior analysis using stratification factors only,2 supporting the robustness of the treatment effect observed with durvalumab plus GemCis. The adjusted HRs herein provide a more refined estimate of the true effect of durvalumab plus GemCis versus placebo plus GemCis on OS, by considering the confounding effect of certain prognostic factors when interpreting treatment effects, an analysis which aligns with regulatory guidance from the US Food and Drug Administration and European Medicines Agency guidelines.9,10 A strength of this analysis is the application of multiple statistical techniques to the same dataset. The AIC backward selection approach was the primary method for identifying prognostic factors due to its suitability for assessing variable etiologic effects. However, all statistical selection methods are exploratory and have limitations. AIC may be prone to overfitting by including irrelevant variables, especially in larger samples, as it penalizes model complexity less heavily than the Bayesian information criterion. Nonetheless, consistency across sensitivity analyses using AIC and the CCS supports the validity of the findings. A limitation of this analysis is the focus on clinical data rather than translational or biomarker data. Prognostic and predictive factors were selected from the literature and pre-specified in TOPAZ-1, potentially overlooking molecular or biologic markers with prognostic value. Overall, this post-hoc analysis of the TOPAZ-1 dataset reinforces the strength of the OS benefit associated with durvalumab plus GemCis in participants with aBTCs. While several potentially prognostic factors were identified, some consistent with those highlighted in prior studies, none were predictive of treatment benefit. These results suggest that treatment with durvalumab plus GemCis may offer clinical benefit across all eligible patients with aBTCs, further supporting its role as a SoC treatment.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
huohaha发布了新的文献求助50
刚刚
刚刚
刚刚
1秒前
1秒前
1秒前
我爱玩原神完成签到,获得积分10
1秒前
allan发布了新的文献求助10
1秒前
1秒前
圆圆发布了新的文献求助10
2秒前
111完成签到,获得积分10
2秒前
科目三的应助被乐观的路人采纳,获得10
2秒前
3秒前
3秒前
华仔的应助被aju采纳,获得10
4秒前
Yxblin发布了新的文献求助10
4秒前
4秒前
5秒前
5秒前
SciGPT的应助被Zxt采纳,获得10
5秒前
熙可檬发布了新的文献求助10
5秒前
皮蛋solo粥发布了新的文献求助10
6秒前
6秒前
sun发布了新的文献求助10
6秒前
小鹿5460的应助被xh采纳,获得10
6秒前
桐桐的应助被荔枝烨采纳,获得10
6秒前
6秒前
思源的应助被搞怪乐珍采纳,获得10
7秒前
8秒前
8秒前
希望天下0贩的0的应助被霏霏采纳,获得10
8秒前
张小白的应助被zxy采纳,获得10
9秒前
lrn发布了新的文献求助10
9秒前
华仔的应助被zxy采纳,获得10
9秒前
JINCHANG完成签到,获得积分10
10秒前
10秒前
11秒前
11秒前
11秒前
12秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
What Else Can I Tell You?: A Pragmatic Study of English Rhetorical Questions as Discursive and Argumentative Acts 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8164445
求助须知:如何正确求助?哪些是违规求助? 9558283
关于积分的说明 21744871
捐赠科研通 7754979
什么是DOI,文献DOI怎么找? 3428582
关于科研通互助平台的介绍 2553119
邀请新用户注册赠送积分活动 2473142